Literature DB >> 908624

Evaluation of live attenuated plague vaccines in Praomys (Mastomys) natalensis.

A F Hallett.   

Abstract

A live attenuated Yersinia pestis vaccine designated EV76-51f, which had previously been shown to be pathogenic in vervet monkeys but not in guinea pigs, was tested in the multimammate mouse Praomys (Mastomys) natalensis. Doses of 10(6) viable organisms inoculated subcutaneously as either a lyophilized suspension or an agar-grown culture resulted in vaccination fatalities in Praomys but not in white mice. Hemagglutinating antibodies to the fraction 1 antigen were not stimulated by doses lower than 10(4) viable organisms. Agar-grown cultures of the vaccine gave better protection against a virulent Y. pestis challenge than did a lyophilized suspension. All Praomys vaccinated with a dose of 10(6) agar-grown EV76-51f protected against a virulent challenge, whereas even doses up to 10(8) lyophilized bacilli failed to give complete protection. The pathogenicity of a live attenuated plague vaccine derived from the Y. pestis EV76 vaccine strain can be detected in Praomys (Mastomys) natalensis, a rodent species highly susceptible to plague. This animal species may therefore be valuable for the testing of live attenuated plague vaccines before they are tested in costly nonhuman primates.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908624      PMCID: PMC421185          DOI: 10.1128/iai.18.1.8-13.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  The basis of virulence in Pasteurella pestis: attempts to induce mutation from avirulence to virulence.

Authors:  T W BURROWS; G A BACON
Journal:  Br J Exp Pathol       Date:  1954-04

2.  Plague in South Africa: a study of the epizootic cycle in gerbils (Tatera brantsi) in the northern Orange Free State.

Authors:  D H DAVIS
Journal:  J Hyg (Lond)       Date:  1953-12

3.  The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms.

Authors:  S R Smithers; R J Terry
Journal:  Parasitology       Date:  1965-11       Impact factor: 3.234

4.  An evaluation of Pasteurella pestis fraction-1-specific antibody for the confirmation of plague infections.

Authors:  T H Chen; K F Meyer
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

5.  Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs.

Authors:  K F Meyer; G Smith; L Foster; M Brookman; M Sung
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Lassa virus infection in Mastomys natalensis in Sierra Leone. Gross and microscopic findings in infected and uninfected animals.

Authors:  J C Demartini; D E Green; T P Monath
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

7.  Immunity in plague: protection induced in Cercopithecus aethiops by oral administration of live, attenuated Yersinia pestis.

Authors:  T H Chen; S S Elbert; D M Eisler
Journal:  J Infect Dis       Date:  1976-03       Impact factor: 5.226

8.  Effectiveness of live or killed plague vaccines in man.

Authors:  K F Meyer
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

9.  Pathogenicity and immunogenic efficacy of a live attentuated plaque vaccine in vervet monkeys.

Authors:  A F Hallett; M Isaäcson; K F Meyer
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

10.  The susceptibility of rodents to schistosome infection, with special reference to Schistosoma haematobium.

Authors:  J H Gear; D H Davis; R J Pitchford
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

View more
  2 in total

1.  Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine.

Authors:  Sarah S Bubeck; Peter H Dube
Journal:  Clin Vaccine Immunol       Date:  2007-07-25

Review 2.  Mastomys Species as Model Systems for Infectious Diseases.

Authors:  Daniel Hasche; Frank Rösl
Journal:  Viruses       Date:  2019-02-21       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.